In vivo inhibition of inducible nitric oxide synthase decreases lung injury induced by Toxocara canis in experimentally infected rats.
The direct effect of nitric oxide (NO) on the viability of Toxocara canis larvae was studied. We observed that the nitric oxide donors, SIN-1 and SNOG, exert no cytotoxic effect on the in vitro viability of T. canis larvae. In addition, we developed a model in rats to elucidate the role of NO during T. canis infection. We evaluated different indicators in four experimental groups: morphological parameters, the total number cells and cell types recovered, nitrite and protein concentration, lactate dehydrogenase and alkaline phosphatase enzymatic activity in the bronchoalveolar lavage fluid, lung index and detection of anti-T. canis specific antibodies. We observed significant differences between non-infected and infected groups. The infected animals treated with the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine were less damaged than infected, non-treated animals. Our results suggest that the in vivo inhibition of the synthesis of NO triggered by iNOS diminishes the deleterious effects of the parasite upon the host, especially the vascular alterations in the lungs. We could show that in vivo production of NO induced by infection with T. canis results in direct host damage. Thus, this induction may constitute an evasion/adaptation mechanism of the parasite.
Espinoza
Elsa Y
EY
Laboratorio de Parasitología, Facultad de Farmacia, Universidad de Salamanca, Spain.
Pérez-Arellano
José L
JL
Carranza
Cristina
C
Collía
Francisco
F
Muro
Antonio
A
D000469:Alkaline Phosphatase / Q000032:analysis / Q000378:metabolism; D000818:Animals; D000917:Antibody Formation; D001992:Bronchoalveolar Lavage Fluid; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000032:analysis / Q000378:metabolism; D007814:Larva / Q000254:growth & development; D007958:Leukocyte Count; D008168:Lung / Q000378:metabolism / Q000469:parasitology* / Q000473:pathology; D023421:Models, Animal; D009569:Nitric Oxide / Q000494:pharmacology* / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D009573:Nitrites / Q000032:analysis / Q000378:metabolism; D051381:Rats; D017166:Toxocara canis / Q000187:drug effects / Q000201:enzymology; D014120:Toxocariasis / Q000209:etiology* / Q000276:immunology / Q000473:pathology
D004791:Enzyme Inhibitors; D006146:Guanidines; D009573:Nitrites; D009569:Nitric Oxide; D007770:L-Lactate Dehydrogenase; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D000469:Alkaline Phosphatase; C004479:pimagedine